N,N'-二乙酰基-L-胱氨酸

N,N'-二乙酰基-L-胱氨酸用途

N,N'-diacetyl-L-cystine (DiNAC) 是一种具有免疫调节特性的 N-乙酰基半胱氨酸的二硫二聚体。N,N'-diacetyl-L-cystine 是啮齿类动物中接触敏感/迟发型超敏反应的有效口服活性调节剂。N,N'-diacetyl-L-cystine 在高脂血症兔 (WHHL) 中也具有抗动脉粥样硬化的作用。

点击显示

N,N'-二乙酰基-L-胱氨酸名称

[ CAS 号 ]:
5545-17-5

[ 中文名 ]:
N,N’-二乙酰-L-胱氨酸

[ 英文名 ]:
N,N'-Diacetyl-L-cystine

[中文别名 ]:

N,N'-二乙酰-L-胱氨酸

[英文别名 ]:

N,N`-Diacetyl-L-cystine
N,N'-Diacetyl-L-cystine
N,N'-diacetyl-cystine
N-acetyl-L-cystine
ACETYL-L-CYSTINE
DiNAC
L-Cystine, N,N'-diacetyl-
Cystine, N,N'-diacetyl-, L-
diacetylcysteine
L-Cystine,N,N'-diacetyl

N,N'-二乙酰基-L-胱氨酸生物活性

[ 描述 ]:

[ 相关类别 ]:

研究领域 >> 心血管疾病

信号通路 >> 其他 >> 其他

[ 靶点 ]

Immunomodulator[1]

[体内研究]

N,N'-二乙酰-L-胱氨酸(DiNAC；0-973.11μg/kg；口服给药；每日；12周；WHHL兔)治疗减少50%胸主动脉动脉粥样硬化,而不影响血浆脂质水平[1]。动物模型：雄性遗传性高脂血症兔(WHHL)兔(10-22周)[1]剂量：0μg/kg,9.73μg/kg或973.11μg/kg给药：口服给药；每日；12周结果：减少50%胸主动脉粥样硬化,不影响血浆脂质水平。

[参考文献]

[1]. Wågberg M, et al. N,N'-diacetyl-L-cystine (DiNAC), the disulphide dimer of N-acetylcysteine, inhibits atherosclerosis in WHHL rabbits: evidence for immunomodulatory agents as a new approach to prevent atherosclerosis. J Pharmacol Exp Ther. 2001 Oct;299(1):76-82.

[2]. Särnstrand B, et al. N,N'-Diacetyl-L-cystine-the disulfide dimer of N-acetylcysteine-is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. J Pharmacol Exp Ther. 1999 Mar;288(3):1174-84.

N,N'-二乙酰基-L-胱氨酸物理化学性质

[ 密度 ]:
1.5±0.1 g/cm3

[ 沸点 ]:
715.5±60.0 °C at 760 mmHg

[ 熔点 ]:
55-72ºC

[ 分子式 ]:
C₁₀H₁₆N₂O₆S₂

[ 分子量 ]:
324.374

[ 闪点 ]:
386.5±32.9 °C

[ 精确质量 ]:
324.044983

[ PSA ]:
183.40000

[ LogP ]:
0.46

[ 外观性状 ]:
白色粉末

[ 蒸汽压 ]:
0.0±5.0 mmHg at 25°C

[ 折射率 ]:
1.583

[ 储存条件 ]:
-15°C

[ 稳定性 ]:
Moisture Sensitive

N,N'-二乙酰基-L-胱氨酸安全信息

[ 海关编码 ]:
29225090

N,N'-二乙酰基-L-胱氨酸合成路线

详细合成路线

N,N'-二乙酰基-L-胱氨酸上下游产品

N,N'-二乙酰基-L-胱氨酸上游产品

N,N'-二乙酰基-L-胱氨酸下游产品

N,N'-二乙酰基-L-胱氨酸文献

Influence of N,N'-diacetyl-L-cystine on D-galactosamine/lipopolysaccharide induced immunological liver failure in mice.

Yao Xue Xue Bao 39(10) , 782-6, (2004)

To study the therapeutic effects of N,N'-diacetyl-L-cystine (DiNAC) on immunological liver failure.Serum ALT, AST and T cell subsets in peripheral blood of the experimental animals during the trial pe...

Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?

Expert Opin. Investig. Drugs 11(5) , 717-20, (2002)

Not all antioxidants reduce atherosclerosis. This may be because atherosclerosis has an autoimmune, inflammatory pathogenesis. As probucol is both an antioxidant and an immunomodulatory drug, it may b...

The new oral immunomodulating drug DiNAC induces brachial artery vasodilatation at rest and during hyperemia in hypercholesterolemic subjects, likely by a nitric oxide-dependent mechanism.

Atherosclerosis 196(1) , 275-82, (2008)

To investigate if the immunomodulator drug DINAC (1) affects arterial dimensions in asymptomatic patients with hypercholesterolemia, (2) has effects on leucocyte markers of inflammation and (3) has in...

更多文献